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INTRODUCTION
Glioblastoma multiforme (GBM) is the most common pri-
mary brain tumor in adults. It also has the highest malignancy 
grade (WHO grade IV) and median survival of 14.6 months 
with surgery, radiation, and chemotherapy [1]. The most sig-
nificant prognostic factors for patients with malignant glioma 
are performance status and age [2]. The paradigm of treatment 
for newly diagnosed patients includes aggressive surgery fol-
lowed by radiation therapy and concomitant temozolomide che-
motherapy. This treatment prolongs median survival to 14.6 
months versus 12.1 months with radiation alone, but essen-
tially all patients recur [1,3]. Despite major aggressive treatment, 
GBM inevitably recurs. GBM also persists due to the hetero-
geneity of the tumor itself [4-6]. The tumor is comprised of di-
fferent cell types including endothelial cells, fibroblasts, in-
flammatory cells, and neurons [7]. 
One of the challenges of implementing a robust anti-tumor 
immune response is the protective immune microenvironment of 
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Glioblastoma multiforme (GBM) is the most common primary brain cancer. Even with aggressive com-
bination therapy, the median life expectancy for patients with GBM remains approximately 14 months. 
In order to improve the outcomes of patients with GBM, the development of newer treatments is criti-
cal. The concept of using the immune system as a therapeutic option has been suggested for several 
decades; by harnessing the body’s adaptive immune mechanisms, immunotherapy could provide a 
durable and targeted treatment against cancer. However, many cancers, including GBM, have devel-
oped mechanisms that protect tumor cells from being recognized and eliminated by the immune sys-
tem. For new immunotherapeutic regimens to be successful, overcoming immunosuppression via im-
mune checkpoint signaling should be taken into consideration. 
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GBM. Specifically, GBM has established mechanisms of dam-
pening the immune response by down regulation of HLA mol-
ecules, expression of immunosuppressive cytokines, increasing 
the activation of T-regulatory (Treg) cells, and increasing the T 
helper cell phenotype [7-9]. A review of the immunosuppres-
sive milieu of GBM is presented elsewhere [90]. This suppres-
sive immune microenvironment created by the tumor is aided 
by the expression of immune checkpoint molecules, which trans-
mit a negative signal to immune cells and decrease their antitu-
mor response. Two checkpoint molecules that are currently 
under investigation in clinical and preclinical studies include 
Cytotoxic T lymphocyte Associated Antigen 4 (CTLA-4) and 
Programmed Death-1 (PD-1). Anti-CTLA-4 was recently FDA 
approved for treatment of metastatic melanoma, and there are 
clinical trials underway investigating other agents such as anti-
PD-1, which may hold promise as treatment for other can-
cers, including GBM [78,79].
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Standard treatment for newly diagnosed GBM includes 
surgical resection with adjuvant radiation and temozolomide. 
In both prospective and retrospective studies, complete surgi-
cal resection leads to increased survival compared to subtotal 
resection or biopsy [10,11]. Of 413 patients with newly diagno-
sed GBM, the median survival for patients who underwent bio-
psy compared to craniotomy was 21 weeks and 45.3 weeks 
respectively [10]. 
Older trials of patients with Grade III-IV gliomas showed 
an increase in survival when radiation was added postopera-
tively, establishing this as standard of care [12,13]. The Brain 
Tumor Study Group performed a prospective trial comparing 
best supportive care with carmustine (BCNU) and radiation 
treatment, alone or in combination [13]. In this study, radioth-
erapy alone or radiotherapy in combination with BCNU con-
ferred a significant survival1 [3]. Similarly, Kristiansen et al. [12] 
reported in a trial of 118 patients, treatment with postopera-
tive radiation with or without bleomycin had a median sur-
vival of 10.8 months versus 5.2 months in patients receiving 
supportive care only. Adjuvant fractionated external beam ra-
diation therapy (EBRT) is typically administered by IMRT in 
2 Gy fractions to a total dose of 60 Gy. Use of higher doses has 
not been found to increase survival [14]. 
1, 3-bis (chloro-ethyl)-1-nitrosourea (BCNU) remained 
the first line chemotherapy for malignant gliomas for several 
years [15]. A small prospective study found that implanting 
BCNU impregnated wafers (Gliadel) after surgery increased 
survival to 53.3 weeks from 39.9 weeks in the placebo arm [16]. 
A larger Phase III trial of 240 patients with malignant glioma 
confirmed this result with a median survival of 13.9 months 
in the Gliadel group vs. 11.6 months in the Gliadel group 
and placebo group respectively [17]. Stupp et al. [1] prospec-
tively investigated the outcome of adding temozolomide (TMZ) 
to adjuvant treatment of GBM. The study found an increase 
in median survival from 12.1 months in the radiation alone 
group to 14.6 months with concomitant and adjuvant TMZ. 
This regimen provided a significant survival advantage with-
out increased toxicity, and has become the new standard of 
care for treatment of newly diagnosed GBM for those pa-
tients not receiving a BCNU wafer.
Recurrence
Most recurrences occur within 1-1.5 years of initial therapy 
and occur within 2 cm of the surgical margins [1]. When patients 
develop disease recurrence, repeat surgery should be considered 
in all patients and is found to have limited complications [18]. 
The value of repeat surgery has been extensively studied in re-
trospective and prospective studies, with various factors found 
to be significantly associated with increased survival. These 
prognostic factors include an increased time interval between sur-
geries [19], age [20], and preoperative Karnofsky Performance 
Scale (KPS) [20,21]. Park et al. [22] created a preoperative scale 
using KPS, tumor volume and tumor location to predict patient 
outcome after repeat surgery for recurrence and can be helpful 
in evaluating a patient for surgery. In patients with diffuse dis-
ease or multiple foci, treatment should be palliative and sup-
portive. 
There is no consensus on the best adjuvant treatment in the 
setting of recurrent disease, although additional chemothera-
py and radiation can be considered as well as enrollment in a 
clinical trial. Data from the following clinical trials are used to 
inform clinicians regarding treatment. BCNU wafers were first 
investigated for management of patients with recurrent malig-
nant glioma and the results from phase III studies reported a 
50% increase in 6 months survival in patients treated with BC-
NU polymers vs. placebo [23]. Bevacizumab, an angiogenesis 
inhibitor, was approved in 2009 for use in recurrent GBM. Data 
from Phase II trials in which patients were treated with beva-
cizumab with or without irinotecan reported median surviv-
al between 7 and 9.2 months [24,25]. Repeat radiation can be 
performed if patients responded well to initial radiation. RTOG 
90-05 defined the maximum tolerated single dose that can be 
given for previously irradiated tumors as 24 Gy, 18 Gy, and 
15 Gy for tumors ≤20 mm, 21-30 mm, and 31-40 mm respe-
ctively [26].
RADIATION
The standard dose of radiation for GBM remains 60 Gy. At-
tempts to increase the dose beyond this limit have not dem-
onstrated a survival advantage and may increase the risk of ra-
dionecrosis [14]. The Radiation Therapy Oncology Group [27] 
studied the effect of adding a stereotactic radiosurgery (SRS) 
boost to conventional EBRT for patients with newly diagnosed 
GBM but found no survival difference between those patients 
receiving SRS compared to those that did not. 
Stereotactic boost
Tsao et al. [28] reviewed the literature and concluded that 
the use of SRS followed by EBRT and BCNU does not show 
any survival benefit. Einstein et al. [29] believed these prior 
studies were limited by the imaging techniques used, therefore 
they devised a Phase II trial utilizing magnetic resonance spec-
troscopy to locate residual tumor prior to administering the 
SRS boost. Median survival for RTOG recursive partitioning an-
alysis class IV patients was 18.7 months compared to 11.1 mon-
ths for patients in the RTOG 93-05 study, showing the poten-
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tial benefit of adding an SRS boost [29]. Additional data suggests 
that giving the SRS boost after EBRT leads to increase in sur-
vival with a median overall survival of 15.1 months for patients 
with newly diagnoses GBM [30]. Several studies have been con-
ducted looking at outcome following SRS for recurrent GBM 
and found median overall survival between 8-10 months fol-
lowing treatment without increased toxicities [30-33].
Brachytherapy
Brachytherapy allows for delivery of higher doses of radia-
tion for initial treatment of GBM. Data from a randomized cl-
inical trial comparing EBRT alone vs. EBRT plus a brachyther-
apy boost of I-125 implants to a dose of 60 Gy, found no di-
fference in survival [34]. A different brachytherapy delivery 
system called Gliasite, is a balloon catheter filled with an aque-
ous iodinated radiation source. The outcomes of patients with 
newly diagnosed GBM receiving Gliasite brachytherapy to a 
median dose of 50 Gy and EBRT to a median dose of 60 Gy 
was retrospectively reviewed and found a median overall sur-
vival of 11.4 months, which is similar to historical controls [35]. 
Brachytherapy has also been investigated in patients with 
recurrent GBM. A retrospective cohort study of 111 patients 
previously treated with surgery, radiation and chemotherapy 
for their primary tumors compared outcomes of patients treat-
ed with brachytherapy, surgery or temozolomide for recurren-
ce [36]. This study found a significant increase in median sur-
vival for patients receiving brachytherapy to 37 weeks, com-
pared to patients who underwent reoperation (30 weeks) or 
dose dense temozolomide (26 weeks) [36]. Additional pro-
spective data showed a median survival of 52 weeks and 64 
weeks respectively, following treatment with repeat resection 
and permanent low activity Iodine 125 brachytherapy [37,38]. 
This approach offers an alternative to temporary brachyther-
apy, which needs to be anchored to the tumor [37,38]. Multi-
ple studies reported a median survival between 35.9-36.4 weeks 
after use of GliaSite (to a median dose of 53-60 Gy) following 
re-resection [39,40]. 
New radiation techniques
New techniques such as thermotherapy, and pulsed reduced 
dose rate radiotherapy (PRDR) were recently studied in pati-
ents with recurrent glioma. Maier-Hauff et al. [41] published 
a study of 59 patients with recurrent GBM receiving iron-ox-
ide nanoparticles combined with fractionated stereotactic ra-
diosurgery and reported a median survival of 13.4 months. 
PRDR is a technique that reduces the dose rate of radiation 
allowing normal tissues to repair while cancer cells remain ra-
diosensitive. 86 patients with Grade 4 recurrent glioma were 
treated with PRDR to a total median dose of 50 Gy. The me-
dian overall survival of these patients from the start of PRDR 
treatment was 5.8 months [42]. 
IMMUNE CHECKPOINT INHIBITORS
Immune checkpoint proteins consist of a group of surface 
proteins and secreted molecules that inhibit over-activation of 
the immune system upon challenge. They are therefore used 
as an immune break to prevent a detrimental effect of the im-
mune response against healthy tissue. The list of immune ch-
eckpoints is long [43-53] with the most well known being 
CTLA-4 and PD-1 with its ligands (PDL1 and PDL2) [54,55]. 
CTLA-4 is expressed exclusively in T cells and antagonizes with 
CD28 for binding to their common ligands CD80 and CD86 
attenuating the immune response against antigens [55-63]. 
PD-1 has a broader distribution than CTLA-4, being expressed 
on the surface of T, B and natural killer cells and is upregulat-
ed upon their activation attenuating the immune response in si-
tu [55]. Cancer in general utilizes immune inhibitory molecules 
to escape elimination by the immune system to further pro-
mote an immunosuppressive microenvironment [55,64-76]. A 
comprehensive review of the available antibodies and the on-
going clinical trials is provided elsewhere [55]. 
The anti-CTLA-4 antibody, Ipilimumab, was approved in 
2011 for the treatment of metastatic melanoma and became 
the first checkpoint inhibitor available on the market [91]. In 
a phase III trial, 676 patients were randomized to receive ei-
ther glycoprotein 100 (gp100) vaccine with ipilimumab, gp100 
alone, or ipilimumab monotherapy [69]. Patients receiving ipi-
limumab monotherapy or in combination with gp100 experi-
enced a significantly longer median overall survival compared 
to those who received gp100 alone (10 months vs. 6.4 months 
respectively) [69].
Extrapolation of these results to patients with brain tumors 
is difficult as many of these trials excluded patients with brain 
metastases. However, blockade of CTLA-4 is currently being 
investigated in patients with central nervous system tumors 
(Table 1). The efficacy of Ipilimumab in patients with brain me-
tastases has been evaluated in prospective studies in patients 
with symptomatic and asymptomatic disease [77]. Median 
overall survival in the asymptomatic cohort was 7 months (95% 
CI 4.1-10.8), and 3.7 (95% CI 1.6-7.3) months in the symp-
tomatic brain metastases group. These patients did not have 
increased toxicity as compared to previous reported patients 
with melanoma without brain metastases [77]. The efficacy 
of anti-CTLA-4 therapy in patients with brain metastases lays 
the groundwork for exploring its efficacy in GBM. A phase I 
clinical trial is recruiting patients to assess the side effects and 
the maximum tolerated dose of the combination of ipilimum-
ab and imatinib mesylate in patients with advanced cancer, 
including patients with intracranial glioblastoma, gliosarco-
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ma and anaplastic astrocytoma [83]. 
Another checkpoint inhibitor being investigated clinically 
is anti-PD-1 and its ligand anti-PDL1. Anti-PD1 was first clin-
ically tested in 39 patients with recurrent solid tumors and de-
monstrated an appropriate safety profile with evidence of anti-
tumor effect [78]. Another recent study by Topalian et al. [79] 
investigated the use of anti-PD-1 in patients with a variety of 
cancer types, including melanoma, non-small cell lung cancer 
(NSCLC), prostate cancer, renal cell carcinoma (RCC) and co-
lorectal cancer. Durable responses of greater than 1 year were 
seen in a percentage of patients with NSCLC, melanoma, and 
RCC. Patients received either 1, 3, or 10 mg/kg of anti-PD-1 
therapy. No dose limiting toxicity was found. The drug was fo-
und to have an acceptable adverse event profile with 14% of pa-
tients experiencing Grade 3 or 4 adverse events, most com-
monly fatigue, GI disorders, decreased appetite, and skin di-
sorders [79]. 
A multicenter phase I clinical trial including patients with 
different types of advanced cancer (75 patients with non small 
cell lung cancer, 55 with melanoma, 18 with colorectal can-
cer, 17 with renal cell carcinoma, 17 with ovarian cancer, 14 
with pancreatic cancer, 7 with gastric cancer and 4 with breast 
cancer) assessed the efficacy and the toxicity of anti-PDL1 an-
tibody. Grade 3 or Grade 4 toxicities were observed in only 9% 
of the patients; partial or complete response was observed in 
6-17% of the patients; 8 out of 16 patients with more than a 
year of follow-up had durable response of at least a year [80].
COMBINATION THERAPY
Traditionally, radiotherapy has served as adjuvant therapy 
in cancer treatment to eliminate the residual disease or as an 
alternative of surgery in inoperable cases. High doses of radi-
ation are used to deplete any radioresistant subpopulations of 
cancer cells in the tumor mass. A recent review describes ra-
diation as an “in situ vaccine” based on the observed absco-
pal effect in various case reports, where systemic disease vir-
tually disappears after treatment with radiosurgery [84]. Al-
though not described in GBM, case reports in patients with 
metastatic melanoma, report the abscopal effect in patients re-
ceiving both radiation and anti-CTLA-4 therapy [85,86]. One 
of the patients had developed brain metastases, which had 
completely resolved at the last follow-up, and developed new 
antibodies to melanoma specific antigens demonstrating a 
systemic immune response [85].
For GBM specifically, this approach has not yet reached 
clinical practice, although the previous case reports show the 
potential of this combination for patients with central ner-
vous system disease. Recent preclinical data showed that com-
bination of radiosurgery with immunotherapy can produce 
long term survivors in GBM challenged mice [81]. Zeng et al. 
[81] characterized the immune profile of long term survivors af-
ter treatment with combined stereotactic radiosurgery with an-
ti-PD1 blockade, showing an increased Teffector/Treg infiltrating 
population in the tumor. Furthermore, surviving mice retained 
systemic immunity when re-challenged with flank tumors 90 
days later, suggesting that this approach generates strong im-
munologic memory [81]. 
Preliminary evidence suggests that this approach of com-
bining radiation with immune checkpoint inhibitors may be 
translated effectively and safely to the clinic. Retrospective data 
of patients with intracranial melanoma metastases who re-
ceived SRS with or without anti-CTLA-4, showed a significant 
improvement in overall survival (21.3 vs. 4.9 months) vs. SRS 
alone, with 47% of patients who received anti-CTLA-4 still 
living at 2 years [82]. 
CONCLUSION
Glioblastoma multiforme continues to be a difficult disease 
to treat despite multiple clinical trials testing the efficacy of 
various chemotherapeutic approaches, survival in patients with 
GBM remains dismal. Immunotherapy suggests that it may 
improve the outcomes of patients with various malignancies, 
Table	1. Ongoing clinical trials in patients with metastatic melanoma in the brain treated with ipilimumab alone or in combination with radio-
therapy 
Study Phase Primary outcome Secondary outcomes Reference
Stereotactic or whole brain radiotherapy  
  in combination with ipilimumab in metastatic  
  melanoma in the brain (NCT10703507)
I Provide the maximum  
  tolerate dose
1. Rate of developing new brain metastases 
2. Response of systemic disease 
3. Overall survival rate 
4. Progression free survival
87
Palliative radiation therapy in combination with  
  ipilimumab in patients with melanoma Grade  
  IV including brain metastases (NCT01449279)
I Safety of the combination  
  therapy
1. Response rate
2. Duration of response
3. Overall survival
88
Use of ipilimumab for the treatment of metastatic  
  melanoma in the brain (NCT00623766)
II Safety and use in combination  
  with corticosteroids
1. Response to treatment and
2. Progression free survival
89
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including GBM. Immune checkpoint inhibitors are currently 
being extensively tested in clinical trials against many cancer 
types in advanced stages. These inhibitors have the potential 
to be a very attractive therapeutic modality used in combina-
tion with other chemotherapy, radiation, or immunomodula-
tory treatments. A multi-modal approach involving these new 
drugs and procedures has the potential to effectively imple-
ment a new paradigm in cancer treatment. 
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